• V J Lewington, A J McEwan, D M Ackery, R J Bayly, D H Keeling, P M Macleod, A T Porter, and M A Zivanovic.
• Department of Nuclear Medicine, Southampton General Hospital, U.K.
• Eur. J. Cancer. 1991 Jan 1; 27 (8): 954-8.

AbstractThe palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. Response was assessed 5 weeks after each treatment. 26 patients were evaluable. Complete pain relief was only reported following strontium-89 injection. Statistical comparison between placebo and strontium-89 showed clear evidence of a therapeutic response to strontium-89 compared with only a limited placebo effect (P less than 0.01).

18 keywords...

hide…